-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] The biopharmaceutical industry is an important industry related to the national economy and people's livelihood, and is closely related to the needs of people's healthy life and the protection of national health and safety
.
Since the beginning of this year, many places have accelerated the pace of development of the biopharmaceutical industry, and sounded a new clarion call for high-quality development of the industry
.
Yunnan's biopharmaceutical industry revenue will reach 400 billion yuan by 2025 The development ideas, principles and goals of the pharmaceutical industry, and the key tasks, main measures and guarantee conditions for industrial development have been deployed
.
The "Plan" proposes that by 2025, the operating income of the biopharmaceutical industry will achieve the goal of "protecting four and fighting five", that is, to ensure that it reaches 400 billion yuan, and strive to reach 500 billion yuan, with an average annual growth of more than 10%.
Among them, the biomedical manufacturing industry should To achieve operating income of more than 150 billion yuan, with an average annual growth of more than 20%
.
The added value of the biopharmaceutical industry reached 120 billion yuan, with an average annual growth rate of more than 10%
.
In addition, the "Plan" also clarifies the key tasks for the development of Yunnan's biomedical industry during the "14th Five-Year Plan" period, including strengthening varieties, giving priority to the development of biotech drugs with a focus on vaccines, modern traditional Chinese medicine represented by formula granules, and Health products based on natural extracts, accelerate the research and development and industrialization of chemical drugs, medical devices, and veterinary drugs, and promote the transformation and upgrading of the biopharmaceutical manufacturing industry
.
Chongqing lists incentives for new biopharmaceutical drugs.
Chongqing's biopharmaceutical industry has a long history of development.
In recent years, it has successively issued the "Guiding Opinions on the Development of the Biopharmaceutical Industry in Chongqing" and "Several Policies for Accelerating the Development of the Biopharmaceutical Industry in Chongqing".
In 2022, the city's biopharmaceutical industry will achieve an output value of 130 billion yuan
.
It is worth noting that not long ago, Chongqing issued the "Several Measures for Accelerating the Development of the Biomedical Industry in Chongqing" (hereinafter referred to as "Measures")
.
In order to speed up the development of the biopharmaceutical industry, the "Measures" propose that, starting from cash rewards, professional title review, internal performance distribution, etc.
, to medical and public health staff who have made important contributions to the completion and transformation of the scientific and technological achievements, and the frontline of clinical research.
Staff and others are inclined to establish an incentive mechanism for clinical research
.
Among them, in terms of new drugs, Chongqing has also listed a list of incentives for this
.
For innovative drugs, improved new drugs and biosimilar drugs (all of the above include biological products, the same below), project support will be established in accordance with the four stages of preclinical research, phase I clinical trials, phase II clinical trials, and phase III clinical trials.
The financial support shall not exceed 20% of the R&D investment, and the maximum financial support intensity is 3 million yuan/item, 2 million yuan/item, 3 million yuan/item, and 7 million yuan/item
.
The output value of Hefei's biopharmaceutical industry will exceed 100 billion yuan in 2025.
At present, Hefei is also vigorously developing the biopharmaceutical industry
.
In this context, the scale of its biopharmaceutical industry has maintained rapid growth in recent years.
Since Hefei was approved to build a new provincial-level biopharmaceutical and high-end medical device base in 2016, the biopharmaceutical industry has developed a strong momentum, and has successively been approved to build a national health care Central Big Data Center, National Regional Medical Center, Yangtze River Delta G60 Science and Technology Innovation Corridor Biopharmaceutical Industry Cooperation Demonstration Park, Provincial Chemical API Base, Provincial Rehabilitation Auxiliary Feature Park, Hefei Comprehensive National Science Center Big Health Research Institute,
etc.
According to the "14th Five-Year Plan for Hefei's Biomedical Industry Development Plan", by 2025, the output value of the city's biomedical industry will exceed 100 billion yuan, and strive to build a national strategic emerging industry cluster
.
Conclusion In addition to the above provinces and cities, this year, many other places have also released documents to vigorously develop the biomedical industry, and proposed to move towards the "100 billion level" market in the next few years
.
In this regard, the industry predicts that under the background of accelerating the development of the biopharmaceutical industry in various places, China's biopharmaceutical industry will continue to move towards high quality, and the results will continue to emerge
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
Since the beginning of this year, many places have accelerated the pace of development of the biopharmaceutical industry, and sounded a new clarion call for high-quality development of the industry
.
Yunnan's biopharmaceutical industry revenue will reach 400 billion yuan by 2025 The development ideas, principles and goals of the pharmaceutical industry, and the key tasks, main measures and guarantee conditions for industrial development have been deployed
.
The "Plan" proposes that by 2025, the operating income of the biopharmaceutical industry will achieve the goal of "protecting four and fighting five", that is, to ensure that it reaches 400 billion yuan, and strive to reach 500 billion yuan, with an average annual growth of more than 10%.
Among them, the biomedical manufacturing industry should To achieve operating income of more than 150 billion yuan, with an average annual growth of more than 20%
.
The added value of the biopharmaceutical industry reached 120 billion yuan, with an average annual growth rate of more than 10%
.
In addition, the "Plan" also clarifies the key tasks for the development of Yunnan's biomedical industry during the "14th Five-Year Plan" period, including strengthening varieties, giving priority to the development of biotech drugs with a focus on vaccines, modern traditional Chinese medicine represented by formula granules, and Health products based on natural extracts, accelerate the research and development and industrialization of chemical drugs, medical devices, and veterinary drugs, and promote the transformation and upgrading of the biopharmaceutical manufacturing industry
.
Chongqing lists incentives for new biopharmaceutical drugs.
Chongqing's biopharmaceutical industry has a long history of development.
In recent years, it has successively issued the "Guiding Opinions on the Development of the Biopharmaceutical Industry in Chongqing" and "Several Policies for Accelerating the Development of the Biopharmaceutical Industry in Chongqing".
In 2022, the city's biopharmaceutical industry will achieve an output value of 130 billion yuan
.
It is worth noting that not long ago, Chongqing issued the "Several Measures for Accelerating the Development of the Biomedical Industry in Chongqing" (hereinafter referred to as "Measures")
.
In order to speed up the development of the biopharmaceutical industry, the "Measures" propose that, starting from cash rewards, professional title review, internal performance distribution, etc.
, to medical and public health staff who have made important contributions to the completion and transformation of the scientific and technological achievements, and the frontline of clinical research.
Staff and others are inclined to establish an incentive mechanism for clinical research
.
Among them, in terms of new drugs, Chongqing has also listed a list of incentives for this
.
For innovative drugs, improved new drugs and biosimilar drugs (all of the above include biological products, the same below), project support will be established in accordance with the four stages of preclinical research, phase I clinical trials, phase II clinical trials, and phase III clinical trials.
The financial support shall not exceed 20% of the R&D investment, and the maximum financial support intensity is 3 million yuan/item, 2 million yuan/item, 3 million yuan/item, and 7 million yuan/item
.
The output value of Hefei's biopharmaceutical industry will exceed 100 billion yuan in 2025.
At present, Hefei is also vigorously developing the biopharmaceutical industry
.
In this context, the scale of its biopharmaceutical industry has maintained rapid growth in recent years.
Since Hefei was approved to build a new provincial-level biopharmaceutical and high-end medical device base in 2016, the biopharmaceutical industry has developed a strong momentum, and has successively been approved to build a national health care Central Big Data Center, National Regional Medical Center, Yangtze River Delta G60 Science and Technology Innovation Corridor Biopharmaceutical Industry Cooperation Demonstration Park, Provincial Chemical API Base, Provincial Rehabilitation Auxiliary Feature Park, Hefei Comprehensive National Science Center Big Health Research Institute,
etc.
According to the "14th Five-Year Plan for Hefei's Biomedical Industry Development Plan", by 2025, the output value of the city's biomedical industry will exceed 100 billion yuan, and strive to build a national strategic emerging industry cluster
.
Conclusion In addition to the above provinces and cities, this year, many other places have also released documents to vigorously develop the biomedical industry, and proposed to move towards the "100 billion level" market in the next few years
.
In this regard, the industry predicts that under the background of accelerating the development of the biopharmaceutical industry in various places, China's biopharmaceutical industry will continue to move towards high quality, and the results will continue to emerge
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
